Evidence map›Paper›PMID 35444500›Full record

ReviewEpilepsy currents

Harnessing Metabolomics to Advance Epilepsy Research.

Tore Eid

Open access · diamondAbstract readReview
In one paragraph

Review in Epilepsy currents. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Tore EidDepartments of Laboratory Medicine, of Neurosurgery, and of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT, USA.ORCID https://orcid.org/0000-0001-9217-6393
Yale New Haven Hospital · US

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Yale Transdisciplinary Collaborative Center for Health Disparities Research (YALE-TCC)U54MD010711 · NIMHD · YALE UNIVERSITY · PI NUNEZ-SMITH, MARCELLA · 2016 to 2021
$14.4M
Network analysis for epilepsy surgeryR01NS109062 · NINDS · YALE UNIVERSITY · PI EID, TORE, ZAVERI, HITTEN P · 2019 to 2022
$1.5M
Metabolomic predictors of circadian vulnerabilities in epilepsyR21NS109734 · NINDS · YALE UNIVERSITY · PI EID, TORE · 2020 to 2020
$461k
NCRR NIH HHS UL1 RR024139NIMHD NIH HHS U54 MD010711NINDS NIH HHS R01 NS109062NINDS NIH HHS R21 NS109734
6 · The paper itself

Abstract

Metabolomics is the laboratory analysis and scientific study of the metabolome-that is, the entire collection of small molecule chemicals in an organism. The metabolome represents the functional state of an organism and provides a multifaceted readout of the aggregate activity of endogenous (cellular) and exogenous (environmental) processes. In this review, we discuss how the integrative and dynamic properties of the metabolome create unique opportunities to study complex pathologies that evolve and oscillate over time, like epilepsy. We explain how the scientific progress and clinical applications of metabolomics remain hampered by biological and technical challenges, and we propose best practices to overcome these challenges so that metabolomics can be used in a rigorous and effective manner to further epilepsy research.

Indexed as

biomarkerschromatographyepileptogenesismass spectrometrymetabolomicsseizure forecasting

Identifiers

PMID35444500
PMCPMC8988727
OpenAlexW4213373602

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.